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Abstract
Therapeutic goals for lipid lowering treatment in the prevention of ischemic heart disease are
often not reached in clinical practice. Even the highest doses of statins do not guarantee good
control of hypercholesterolemia in all patients. Therefore, new lipid lowering drugs are being
investigated. One of them is ezetimibe  intestinal cholesterol absorption inhibitor. Treatment
with ezetimibe results in significant reduction of total cholesterol and LDL cholesterol levels.
It is hoped that concomitant treatment with ezetimibe and other lipid lowering drugs (particu-
larly statins) will be more effective. In large randomized clinical trials, co-administration of
ezetimibe with atorvastatin and simvastatin proved to be more effective in lowering cholesterol
levels and reaching target therapeutic levels than treatment with statin alone. In addition,
combined treatment with ezetimibe and simvastatin was more effective compared to treatment
with todays most effectively used statin (rosuvastatin) alone. Reduction of statin dose, due to
the combined treatment with ezetimibe, lowers the risk of adverse events. Results of the pub-
lished studies suggest that ezetimibe is safe and when administered together with statin does
not increase the risk of liver or muscle damage. Treatment with ezetimibe may be regarded as
a new option in the management of patients who need lipid lowering treatment. (Cardiol J
2007; 14: 232237)
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Introduction
The role of dyslipidemia as a risk factor for
cardiovascular disease is well documented. Despite
the fact that the benefits of lowering cholesterol
levels have been widely known for a long time, ther-
apeutic goals in medical association recommenda-
tions concerning the prevention of ischemic heart
disease are rarely met in clinical practice [1]. In
some reports, it has been shown that only 49% of
patients with coronary heart disease meet the
criteria of LDL level below 3.5 mmol/L and only in
10% of patients LDL level is decreased below
2.6 mmol/L [1]. It is especially difficult to reach rec-
ommended targets in patients with initially very
high cholesterol levels. Therefore, alternative
modes of treatment are being investigated.
One of the possible options which attracted the
attention of investigators is intervention on choles-
terol absorption in the small intestine. Dietary cho-
lesterol in the gastrointestinal tract (exogenous) as
well as the cholesterol produced by the liver and
excreted with bile and cholesterol derived from
desquamating epithelial cells (endogenous) is emul-
sified and accumulated in micelle. It is transported
by brush border in this form to enterocytes, where,
after esterification, it is packed into chylomicrons [2].
The precise mechanism of cholesterol absorption is
not known. Recently the NPC1L1 protein has been
identified as a putative cholesterol transporter
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and site of action of the new lipid lowering drug,
ezetimibe, in intestinal cells. Ezetimibe is the first
drug of the 2-azetidinone group of drugs, which
block NPC1L1 protein [3]. The structure of
NPC1L1 protein is similar to the structure of NPC1
protein which plays an important role in intracellu-
lar cholesterol transport and which gene defect
causes lipid storage disease Niemann-Pick type C.
The NPC1L1 protein is also expressed in liver cells
and probably plays a significant role in the devel-
opment of diet-induced fatty liver [4].
It is estimated that ezetimibe lowers diet cho-
lesterol absorption in the intestine by over 50% [5].
Ezetimibe-glucuronide is the pharmacologically
active form of the drug with bioavailability of 80%,
and maximal concentration of the drug is reached
in 12 hours after administration. The estimated
half-time of ezetimibe in the serum is 22 hours [6].
Pharmacological intervention in the process of
cholesterol absorption appears to be an important
and promising method to improve efficacy of low-
ering serum cholesterol [7]. Ezetimibe is especial-
ly effective when combined with cholesterol syn-
thesis inhibitor-statins. Increased cholesterol syn-
thesis in the liver resulting from cholesterol
absorption inhibition in the intestine is prevented
by statins. This strategy of simultaneous inhibition
of absorption and synthesis of cholesterol seems to
be very promising.
Ezetimibe is administered in a single dose of
10 mg p.o. in the evening or in the morning without
regard to food. Age, sex or race of the patients do not
affect ezetimibe efficacy. Ezetimibe does not affect
absorption of fatty acids, triglycerides, fat-soluble vi-
tamins or bile acids. Considering the frequent need
to use multiple drugs on one patient, it is of note that
ezetimibe does not influence the concentration of oth-
er drugs such as statins, fibrates, digoxin or warfarin.
Gemfibrozil and fenofibrate increase ezetimibe con-
centration in the serum while resins increase its ex-
cretion. Therefore, resins and ezetimibe should be
administered a few hours apart [6, 8].
In recent years, the efficacy of ezetimibe has
been compared to placebo and other lipid lowering
drugs.
Monotherapy with ezetimibe vs. placebo
The results of randomized, multicentre stud-
ies comparing the efficacy of ezetimibe with place-
bo were very promising [9, 10]. Administration of
10 mg of ezetimibe once daily in patients with pri-
mary hypercholesterolemia resulted in lowering of
LDL cholesterol by 18.2% (p < 0.01) and total
cholesterol by approximately 12% (p < 0.01). Treat-
ment with ezetimibe also resulted in significant
reduction of non-HDL cholesterol, triglycerides and
apolipoprotein B. The response to ezetimibe admin-
istration did not differ significantly between the
studied groups. The drug was well tolerated, and
its safety profile was similar to the placebo.
Co-administration of ezetimibe and statin
Studies evaluating the efficacy of concomitant
treatment with statin and ezetimibe have been con-
ducted for a few years [1116]. The recently pub-
lished meta-analysis of 3 studies [17] which includ-
ed 3,083 patients with primary hypercholesterole-
mia, showed that co-administration of ezetimibe and
simvastatin compared to treatment with simvasta-
tin alone resulted in greater reduction of LDL cho-
lesterol levels. Twelve weeks of combined treat-
ment with ezetimibe and simvastatin lowered LDL
cholesterol by 50%, whereas monotherapy with
statin resulted in a reduction of less than 40%.
Administration of ezetimibe and simvastatin was as-
sociated with a significant increase of percentage
of patients who met target LDL cholesterol levels:
Nearly 50% more subjects reached treatment goals
recommended by ATPIII (Adult Treatment Panel III
[18])  LDL cholesterol concentration < 2.6 mmol/l
(79% vs. 42%). At the same time, combined treat-
ment resulted in LDL cholesterol level < 1.8 mmol/l
6 times more often compared to treatment with sta-
tin alone (37% vs. 6%), and such treatment was as-
sociated with a significant reduction of non-HDL
cholesterol, apolipoprotein B and triglycerides in
both young and older patients. The results did not
differ significantly between age groups; concomi-
tant treatment with ezetimibe and simvastatin was
more effective in both groups: patients > 65 years
and < 65 years of age [16].
It has also been demonstrated in the studies
that ezetimibe administered with statin significantly
lowers LDL cholesterol concentration in patients
with chronic renal failure who are also on dialysis.
In the UK-HARP-II study (The Second United
Kingdom Heart and Renal Protection), the addition
of ezetimibe (10 mg) to simvastatin (20 mg) result-
ed in additional lowering of LDL levels by 21%.
Ezetimibe was well tolerated in this group of pa-
tients, did not cause an increase in creatinine lev-
els and did not affect absorption of fat-soluble vita-
mins. Therefore, ezetimibe might also be a valua-
ble treatment in this group of patients [19].
The efficacy of ezetimibe was also evaluated in
combination with atorvastatin and, as with simvastatin
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combination therapy, was more effective when com-
pared to monotherapy. In one of study which en-
rolled 450 subjects with LDL cholesterol levels
> 2.6 mmol/L, ezetimibe and a placebo were added
to the treatment despite administration of atorvas-
tatin (1020 mg daily). Incidence of reaching target
levels of LDL cholesterol (< 2.6 mmol/L) were
above 80% of patients in the ezetimibe group and
only 20% of patients in the placebo group [20].
In the VYVA study (Vytorin vs Atorvastatin)
[21], it was demonstrated that co-administration of
ezetimibe with atorvastatin (atorvastatin doses of
10, 20, 40 and 80 mg) resulted in greater reduction
of LDL cholesterol levels (4759% depending on
the dose of atorvastatin) compared to monothera-
py with atorvastatin (3653%). Similarly, triglycer-
ide levels were significantly further reduced in the
group treated with both ezetimibe and atorvastatin.
The target level of LDL cholesterol (according to
ATP III recommendations) was reached in more
patients in the group treated with two drugs. In
addition, co-administration of ezetimibe and simv-
astatin (20 mg), as compared to the treatment with
atorvastatin (20 mg) in 435 patients with LDL cho-
lesterol > 2.6 mmol/L (despite previous treatment
with atorvastatin 10 mg), more often resulted in
a reduction of LDL cholesterol levels. Moreover,
LDL cholesterol concentrations < 2.6 mmol/l were
more often observed in the group of patients treat-
ed with two drugs [22].
In a recent American study EASE (Ezetimibe
Add-on Statin for Effectiveness) [23] which includ-
ed 3,030 patients with hypercholesterolemia, it was
found that adding ezetimibe (10 mg) to statin ther-
apy resulted in additional reduction of LDL choles-
terol levels by 25.8%. Statins used in this study
were: atorvastatin (in 37.6% of studied subjects),
simvastatin (29.4%), pravastatin (20.4%), lovasta-
tin (6.9%) and fluvastatin (5.3%). Co-administration
of ezetimibe and statin resulted in significantly
more patients (71% in the group treated with two
drugs vs. 20.6% in statin monotherapy group) reach-
ing target LDL cholesterol levels after 6 weeks of
treatment.
The results of meta-analysis of 14 studies com-
paring monotherapy with rosuvastatin (5, 10, 20 and
40 mg) with combination therapy  ezetimibe and
simvastatin (10 mg/10 mg, 10 mg/40 mg, 10 mg/80 mg;
ezetimibe and simvastatin doses, respectively) in
patients with primary hypercholesterolemia [23] are
also very interesting. Meta-analysis results suggest
that therapy with ezetimibe added to simvastatin is
more effective than monotherapy with rosuvasta-
tin alone. Percentage reductions from baseline in
LDL-cholesterol were 50.6% and 47.4% for
ezetimibe/simvastatin 10 mg/10 mg and rosuvas-
tatin 5 mg, respectively. Similar results were ob-
served in patients treated with higher doses. In
view of the above mentioned results, head-to-head
studies comparing the efficacy of rosuvastatin (the
most effective statin currently used) and combi-
nation therapy with ezetimibe and simvastatin are
needed [24].
Currently, further studies are being performed
to evaluate the efficacy of combination therapy
 SHARP (Study of Heart and Renal Protection),
SEAS (Simvastatin and Ezetimibe in Aortic Steno-
sis), ENHANCE (Ezetimibe and Simvastatin in Hy-
percholesterolemia Enhances Atherosclerosis Re-
gression) and IMPROVE IT (Improved Reduction of
Outcomes: Vytorin Efficacy International Trial) [25].
Combination therapy with
ezetimibe and fibrate
High incidence of mixed hyperlipidemia forced
the investigators to evaluate the efficacy of combi-
nation therapy with ezetimibe and fibrate. Data
on co-administration of ezetimibe and fibrate are
scarce but promising. In one study, which included
626 patients with mixed hyperlipidemia [26], the ef-
ficacy of 10 mg ezetimibe, 160 mg fenofibrate and
10 mg ezetimibe co-administered with 160 mg of
fibrate and placebo were evaluated. After 12 weeks
of therapy, in the combination therapy group a sig-
nificant reduction of triglyceride levels (44%) and
an increase in HDL levels (by 19%) were observed.
Co-administration of ezetimibe and fenofibrate re-
sulted in greater reduction of LDL-cholesterol (by
20.4%), non-HDL cholesterol (by 30.4%) and apo-
lipoprotein B levels compared to monotherapy with
fenofibrate or ezetimibe.
Effects of ezetimibe on endothelium
Lipid lowering therapy constitutes the basis of
cardiovascular disease prevention, particularly in
high-risk patients. The beneficial effects of treat-
ment with statins on cardiovascular morbidity and
mortality are well known. However, this is due not
only to the lipid lowering effects of statins but also
to their pleiotropic activity [27]  beneficial effect
on endothelium, inflammation, oxidative stress and
smooth muscle cells proliferation [28]. There is
a need to evaluate whether or not ezetimibe has
similar properties.
Balut et al. [29] performed an interesting study
concerning the influence of treatment with various
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lipid lowering drugs on endothelium function evalu-
ated by measuring forearm blood flow in 14 male pa-
tients with metabolic syndrome. Endothelium-de-
pendent vasodilatation and an increase in blood flow
were better with combination therapy (ezetimibe
10 mg and atorvastatin 10 mg) vs. treatment with ator-
vastatin alone even at higher doses (40 mg).
On the other hand, Landmesser et al. [30] did
not observe any significant pleiotropic effect of
ezetimibe. In this study, 20 patients with chronic
heart failure were treated with ezetimibe or simv-
astatin for four weeks. Endothelial function im-
proved significantly only in the group treated with
simvastatin. The authors observed that treatment
with simvastatin increased the number of progeni-
tor cells whereas ezetimibe had no such effect [29].
Similar results were observed in another study by
Fichtlscherer et al. [31]. In four groups of patients
with ischemic heart disease, four different methods
of lipid lowering therapy were used: ezetimibe 10 mg,
ezetimibe 10 mg and simvastatin 20 mg, and atorv-
astatin in increasing doses 1040 mg and atorvas-
tatin 40 mg. After four weeks, endothelial function
was evaluated. Neither ezetimibe in monotherapy
nor ezetimibe combined with 20 mg simvastatin
were associated with an increase in forearm blood
flow. This effect was only observed in two groups
treated with statins. Therefore, it was suggested
that adding ezetimibe to statin might abolish its plei-
otropic activity [32]. Further studies to elucidate the
possible influence of ezetimibe on endothelial func-
tion are needed.
Effects of ezetimibe on
C-reactive protein level
Significant association between C-reactive pro-
tein level (CRP)  inflammation marker and car-
diovascular risk has been found in many studies
[33]. CRP level can be reduced by statins, which is
thought to be the mechanism of their pleiotropic
activity. Ezetimibe, however, can have a similar
effect. Sager et al. [34] investigated the effect of
simvastatin and combination therapy with statin and
ezetimibe on CRP concentration in over 1,000 pa-
tients. Adding ezetimibe to simvastatin resulted in
a two-fold greater reduction in CRP concentration
compared to treatment with simvastatin alone.
Treatment with 10 mg ezetimibe and 80 mg simv-
astatin resulted in a 40% reduction in CRP level
compared to a 20% reduction with 80 mg simvasta-
tin alone. Similar observations were made by Feld-
man et al. [17] in the meta-analysis in which the
efficacy of co-administration of ezetimibe and sim-
vastatin with respect to CRP levels in different age
groups was examined. As it has been found that
monotherapy with ezetimibe does not lower CRP
levels [35]; the mechanism of the synergistic effect
of ezetimibe and simvastatin is not clear. Possibly
ezetimibe increases its beneficial effect on CRP
levels by increasing the lipid-lowering activity of
statin. This issue will be the subject of future stud-
ies and publications.
Side effects of ezetimibe
The high lipid lowering efficacy of ezetimibe
in combination with statin raises question of its safe-
ty. In large studies, the safety profile of ezetimibe
was good. It seems that ezetimibe in combination
with statin does not increase the risk of muscle or
liver damage. In some studies a slight increase in
liver enzymes or creatine kinase was observed in
12% of studied subjects, and they returned to nor-
mal after drug was stopped [17, 36]. Side effects
with statin (administered alone) occurred in 34%
of patients [37]. Moreover, in the VYVA study,
a long lasting increase in liver enzymes was ob-
served significantly more often in the group treat-
ed with atorvastatin alone (doses 10, 20, 40, 80 mg)
vs. group of patients treated with ezetimibe and sim-
vastatin (10, 20, 40, 80 mg, respectively) [25]. Nev-
ertheless, rare cases of serious liver damage dur-
ing treatment with ezetimibe have been reported.
Two types of side effects were observed: serious
cholestatic hepatitis and acute immune hepatitis
[36]. Three cases of myopathy were reported dur-
ing treatment with ezetimibe (one of them in a pa-
tient treated with ezetimibe and atorvastatin) [38]
and two during monotherapy with ezetimibe [39].
The underlying mechanism remains unknown.
Summary
Ezetimibe appears to be a promising new lipid
lowering drug. It has been found that lowering to-
tal cholesterol by 1% decreases all-cause mortality
by 1.1% and coronary heart disease mortality by
1.5% [40]. Assuming that ezetimibe reduces total
cholesterol concentration by around 12%, treatment
with this drug could result in a 13% reduction in
total mortality and 18% in coronary heart mortali-
ty. However, there is continuing debate about the
overall clinical benefit of ezetimibe. In order to elu-
cidate the role of ezetimibe in atherosclerosis pre-
vention, further large studies evaluating its effect
on cardiovascular risk are needed. In some coun-
tries, ezetimibe (10 mg) is already on the market.
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In the US and a few European countries, a combi-
nation of ezetimibe (10 mg) and simvastatin (in 10,
20, 40 and 80 mg doses) is already registered. Last
year ezetimibe was also registered in Poland.
It appears that combination therapy may be the
treatment of choice in hyperlipidemia in patients not
tolerating statins in high doses. The other group of
patients who may benefit from ezetimibe treatment
are those who do not respond to statins probably
due to increased absorption of dietary cholesterol.
In this group of patients, endogenous cholesterol
synthesis (with HMG-CoA reductase) has less in-
fluence on its serum level [41]. It should be noted,
however, that margarines which have been availa-
ble in Poland for some years contain stanols
 semi-synthetic phytosterols (steroids contained
in plant products) derivatives [42]. Stanols also sup-
press cholesterol absorption in the intestine and
reduce serum cholesterol levels by several percent.
In contrast to ezetimibe, stanols make dietary
pharmacotherapy possible as they can be added to
food products. Nevertheless, treatment with
ezetimibe opens new therapeutic options for pa-
tients who need lipid lowering therapy.
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